Shares in Affymetrix Up 17 Percent; UBS Upgrades Stock | GenomeWeb
NEW YORK (GenomeWeb News) — Shares in Affymetrix were up 17.74 percent, or $4.09, at $26.72 this afternoon after the company yesterday released its third-quarter earnings.
 
Today, investment bank UBS upgraded its rating of Affy shares to ‘Neutral’ from ‘Reduce.’
 
As GenomeWeb News reported yesterday, Affy said that third-quarter revenue increased around 1 percent as last year's profit swung to a loss.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: carbapenem resistance in Enterobacteriaceae, selection against educational attainment-linked variants, and more.

Technology Review points out that a new US presidential science advisor hasn't been selected.

Researchers find that blood tests might be able to help determine severity of a concussion, Wired reports.

President-elect Donald Trump considers other candidates for director of the National Institutes of Health, Nature News reports.